Loading patent…
AssigneeMax-Planck-Gesellschaft Zur Foerd Der Wissen. E.V.
InventorsStefan Stamm, Athena Andreadis, Michel Goedert, Annette Hartmann, Peter Stoilov, Oliver Stoss
Estimating the term…
The present inventions relates to substances which are capable of controlling the inclusion of exon (10) of the tau gene. The substances can reverse “wrong” tau splicing pattern and. Since “wrong” tau splicing patterns are associated with tauopathies that cause dementia, the substances can be used as therapeutic agents. The invention also provides a method for testing substances that control tau exon (10) inclusion. The method is suitable for a high throughput screening. Additional products which are useful for changing tau exon (10) expression or for performing the test method are described as well.
A substance which is capable of controlling the inclusion of exon 10 of the tau gene for use as a therapeutic agent.
A process for changing the pre-mRNA processing relating to the tau gene of a mammalian cell, which comprises exposing the cell with a substance which is capable of controlling the inclusion of exon 10 of the tau gene.
A method for testing substances that control the inclusion of exon 10 of the tau gene, comprising the steps of:
The method according to claim 23, wherein the cells are transfected with a DNA which is a minigene construct as defined in any one of claims 29 to 31.
A minigene construct comprising the following DNA elements derived from the tau gene:
Dependencies are inferred from the claim text.